09.08.2022 - - FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS - On track to report initial Phase 1 clinical data for FHD-609 in synovial .
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update -FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues. | August 9, 2022
Covid and the new spirit of collaboration politico.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from politico.com Daily Mail and Mail on Sunday newspapers.